IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression free survival, help stop or slow progression of their disease, as well as the degree to which treatment efficacy would allow them to maintain functional ability and their quality of life with minimal side effects.
For more information and to read the final report, click here.
Read the full press release here.